A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
Yundong He
(Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science)
Ting Wei
(Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine and Science)
Zhenqing Ye
(Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine and Science)
Jacob J. Orme
(Division of Medical Oncology, Department of Internal Medicine, Mayo Clinic College of Medicine and Science)
Dong Lin
(Department of Experimental Therapeutics, BC Cancer Research Centre)
Haoyue Sheng
(Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science)
Ladan Fazli
(Department of Experimental Therapeutics, BC Cancer Research Centre)
R. Jeffrey Karnes
(Department of Urology, Mayo Clinic College of Medicine and Science)
Rafael Jimenez
(Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine and Science)
Liguo Wang
(Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine and Science)
Liewei Wang
(Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine and Science)
Martin E. Gleave
(The Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia)
Yuzhuo Wang
(Department of Experimental Therapeutics, BC Cancer Research Centre)
Lei Shi
(Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science)
Haojie Huang
(Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science)
Resistance to second generation anti-androgen therapies such as enzalutamide (ENZ) can emerge in prostate cancer patients. Here, the authors identify an ENZ-resistant mechanism driven by AR-dependent transcription of noncanonical targets that make resistant cells susceptible to dual inhibition of BET and CBP/p300 signaling.
Yundong He, Ting Wei, Zhenqing Ye, et al. (2021). "A noncanonical AR addiction drives enzalutamide resistance in prostate cancer". Nature Communications. https://doi.org/10.1038/s41467-021-21860-7